echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > [Cell Sub-Journal] Researchers discover the mechanism that controls the formation of tertiary lymphoid structures of prognostic "potential stocks"!

    [Cell Sub-Journal] Researchers discover the mechanism that controls the formation of tertiary lymphoid structures of prognostic "potential stocks"!

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This article is original for Translational Medicine.
    Please indicate the source when reprinting.
    Author: Sibyl Introduction: Tertiary lymphatic structures usually appear outside the lymphatic system
    .

    They are rich in immune cells and have similar tectonic functions to structures such as lymph nodes
    .

    However, we know very little about the reasons for the formation of tertiary lymphoid structures
    .

    A new study shows that inhibiting the secretion of SATB1 protein in T cells of cancer patients differentiates large numbers of Tfh cells
    .

    Tfh cells react with B cells to form tertiary lymphoid structures in the tumor, making the tumor develop more slowly, thus prolonging the life of cancer patients
    .

    Moffitt Cancer Center researchers recently published an article in Immunity titled: "TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures
    .
    "
    The article points out the molecular and cellular mechanisms that control the formation of tertiary lymphoid structures in tumors
    .

    https://doi.
    org/10.
    1016/j.
    immuni.
    2021.
    12.
    007The human immune system is made up of different types of cells that secrete proteins that affect cancer development, including T cells and B cells
    .

    T cells are further classified according to their functions and molecular properties: follicular helper T cells (Tfh) and follicular regulatory T cells (Tfr)
    .

    These different kinds of immune cells interact and influence the development of cancer
    .

    Tfh cells stimulate B cells to produce antibodies, while Tfr cells inhibit B cell activity
    .

    They are found in lymph nodes along with other immune cells, and they are also found in tertiary lymphoid structures
    .

    The study found that patients with tumors of the tertiary lymphoid structure had a better prognosis and a better response to immunotherapy
    .

    Scientists speculate that immune cells and their secreted proteins in the tertiary lymphoid structure promote the immune system's ability to defend against tumor cells
    .

    However, this structure is rarely found in mouse model experiments, so the reason for its formation is unknown
    .

    The researchers conducted a series of experiments to better understand the molecular and cellular mechanisms that lead to the formation of tertiary lymphoid structures
    .

    By studying cells and mouse models, they found that SATB1 protein plays an important regulatory role in the differentiation of Tfh and Tfr cells
    .

    SATB1 is a tissue-specific nuclear matrix-binding protein that anchors to specific DNA sequences in a unique cage-like structure and recruits chromatin remodeling factors to regulate gene transcription
    .

    The researchers found that inhibiting the secretion of SATB1 protein can promote the differentiation of Tfh cells and prevent the formation of Tfr cells
    .

    They also found some key molecules involved in this process, such as ICOS and TGF-β
    .

    The researchers verified that mice without SATB1 protein in T cells have a larger proportion of Tfh cells, which can react with B cells to form tertiary lymphoid structures in tumors
    .

    This also shows the importance of SATB1 in this process
    .

    They also found that the tumors in the mice injected with Tfh cells developed more slowly compared with the control experiments in which the T cells were injected, which is also closely related to the tertiary lymphoid structure within the tumor
    .

    The researchers hope their findings can lead to new treatments to control the formation of tertiary lymphoid structures in unresectable tumors and better anti-cancer immunotherapy
    .

    Dr.
    Jose Conejo-Garcia Moffitt Cancer Immunology Research Center director, said: "Approximately 20% of cancer patients have three lymphoid structures
    .

    Experimental data, we believe that in metastatic tumors and unresectable tumors, autologous Antigenic Tfh cells can promote the formation of tertiary lymphoid structures
    .

    Anti-tumor T cells in this structure can provide a protective barrier and stimulate immune efficacy to delay the development of advanced malignant tumors, thereby improving the effect of immunotherapy
    .

    Reference: https :// Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment plans
    .

    If you need health guidance, please go to a regular hospital for treatment
    .

    Popular·ArticleBasic Research【Science Sub-Journal】Artificial Lung Modification - Lizard Provides Amazing Method! Intestinal flora [Nature] hypoglycemic drugs are ineffective? Because gut microbiota is responsible for cancer treatment [PNAS] Chinese herbal medicines thyme and oregano have discovered anti-cancer compounds Disease diagnosis and treatment [Nature sub-journal] One step closer to changing the $70 billion global diagnostic industry! Protein biosensor measures toxic drugs in cancer, arthritis and organ transplant patients Cardiovascular disease [JAMA Sub] Are you stressed? Stress increases cardiovascular risk! Why do pain and anxiety increase breathing rate? The scientific research "Science" announced the breakthrough in 2021: a problem that has plagued biologists for 50 years was solved by AI and realized the dream of a Nobel Prize winner!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.